Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se

Journal of Leukocyte Biology

Volumn 94, Issue 2, 2013, Pages 377-383

  Su, Yan ^a,b   Rossi, Robert ^a,b   De Groot, Anne S ^c,d   Scott, David W ^a,b  

^a Uniformed Services University of the Health Sciences   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c EpiVax   (United States)

^d UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Immunomodulation; IVIg; Treg

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH2 CELL;

IMMUNOMODULATION; IVIG; TREG;

ADOPTIVE TRANSFER; ANIMALS; EPITOPES, T-LYMPHOCYTE; FORKHEAD TRANSCRIPTION FACTORS; IMMUNE TOLERANCE; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON-GAMMA; ISOANTIBODIES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OVALBUMIN; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 84880992500     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.0912441     Document Type: Article

References (37)

1. Bluestone, J. A., Abbas, A. K (2003) Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3, 253-257.
2. Tang, Q., Bluestone, J. A. (2008) The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 9, 239-244.
3. Gambineri, E., Torgerson, T. R., Ochs, H. D. (2003) Immune dysregula-tion, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr. Opin. Rheumatol. 15, 430-435.
4. Malek, T. R., Yu, A, Vincek, V., Scibelli, P., Kong, L. (2002) CD4 regulatory T cells prevent lethal autoimmunity in IL-2R/3-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17, 167-178.
5. Kim, J. M., Rasmussen, J. P., Rudensky, A. Y. (2007) Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8, 191-197.
6. Achiron, A, Gabbay, U., Gilad, R, Hassin-Baer, S., Barak, Y, Gornish, M., Elizur, A, Goldhammer, Y, Sarova-Pinhas, I. (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50, 398-402.
7. Bayry, J., Lacroix-Desmazes, S., Kazatchkine, M. D., Kaveri, S. V. (2007) Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nature clinical practice. Rheumatology 3, 262-272.
8. Negi, V. S., Elluru, S., Siberil, S., Graff-Dubois, S., Mouthon, L., Kazatchkine, M. D., Lacroix-Desmazes, S., Bayry, J., Kaveri, S. V. (2007) Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J. Clin. Immunol. 27, 233-245.
9. Nimmerjahn, F., Ravetch, J. V. (2008) Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26, 513-533.
10. Ephrem, A, Chamat, S., Miquel, C, Fisson, S., Mouthon, L., Caligiuri, G, Delignat, S., Elluru, S., Bayry, J., Lacroix-Desmazes, S., Cohen, J. L., Salomon, B. L., Kazatchkine, M. D., Kaveri, S. V., Misra, N. (2008) Expansion of CD4 + CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111, 715-722.
11. Jain, R, Tartar, D. M., Gregg, R K, Divekar, R D., Bell, J. J., Lee, H. H., Yu, P., Ellis, J. S., Hoeman, C. M., Franklin, C. L., Zaghouani, H. (2008) Innocuous IFN7 induced by adjuvant-free antigen restores nor-moglycemia in NOD mice through inhibition of IL-17 production. J. Exp. Med. 205, 207-218.
12. Divekar, R D., Haymaker, C. L., Cascio, J. A, Guloglu, B. F., Ellis, J. S., Tartar, D. M., Hoeman, C. M., Franklin, C. L., Zinselmeyer, B. H., Lynch, J. N., Miller, M. J., Zaghouani, H. (2011) T cell dynamics during induction of tolerance and suppression of experimental allergic encephalomyelitis. J. Immunol. 187, 3979-3986.
13. Skupsky, J., Su, Y, Lei, T. C, Scott, D. W. (2007) Tolerance induction by gene transfer to lymphocytes. Curr. Gene. Ther. 7, 369-380.
14. Scott, D. W., Zhang, A. H., Su, Y (2012) B-cell based gene therapy for autoimmune diseases. Infect. Dis. Drug Targets 12, 241-247.
15. Lei, T. C, Scott, D. W. (2005) Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood 105, 4865-4870.
16. Soukhareva, N., Jiang, Y, Scott, D. W. (2006) Treatment of diabetes in NOD mice by gene transfer of Ig-fusion proteins into B cells: role of T regulatory cells. Cell. Immunol. 240, 41-46.
17. De Groot, A. S., Moise, L., McMurry, J. A, Wambre, E., Van Overtvelt, L., Moingeon, P., Scott, D. W., Martin, W. (2008) Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 112, 3303-3311.
18. Cousens, L. P., Tassone, R, Mazer, B. D., Ramachandiran, V., Scott, D. W., De Groot, A. S. (2013) Tregitope update: mechanism of action parallels IVIg. Autoimmun. Rev. 12, 436-443.
19. Cousens, L., Mingozzi, F., van der Marel, S., Su, Y, Garman, R, Fer-reira, V., Martin, W., Scott, D. W., De Groot, A. S. (2012) Teaching tolerance: new approaches to enzyme replacement therapy for Pompe disease. Hum. Vaccin. Immunother. 8, 1-6.
20. Cousens, L. P., Su, Y, McClainea, E., Li, X., Terry, F., Smith, R, Leed, J., Martina, W., Scott, D. W., De Groot, A. S. (2013) Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. J. Diabetes Res. doi: http://dx.doi.org/10.1155/2013/621693 [Epub ahead of print].
21. Zambidis, E. T., Scott, D. W. (1996) Epitope-specific tolerance induction with an engineered immunoglobulin. Proc. Natl. Acad. Sci. USA 93, 5019-5024.
22. Zambidis, E. T., Barth, R K, Scott, D. W. (1997) Both resting and activated B lymphocytes expressing engineered peptide-Ig molecules serve as highly efficient tolerogenic vehicles in immunocompetent adult recipients. J. Immunol. 158, 2174-2182.
23. Melo, M. E., Qian, J., El-Amine, M., Agarwal, R K, Soukhareva, N., Kang, Y, Scott, D. W. (2002) Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases. J. Immunol. 168, 4788-4795.
24. Xu, B., Scott, D. W. (2004) A novel retroviral gene therapy approach to inhibit specific antibody production and suppress experimental autoimmune encephalomyelitis induced by MOG and MBP. Clin. Immunol. 111, 47-52.
25. Zhang, A. H., Li, X., Onabajo, O. O., Su, Y, Skupsky, J., Thomas, J. W., Scott, D. W. (2010) B-cell delivered gene therapy for tolerance induction: role of autoantigen-specific B cells. J. Autoimmun. 35, 107-113.
26. Agarwal, R K, Kang, Y, Zambidis, E., Scott, D. W., Chan, C. C, Caspi, R R (2000) Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J. Clin. Invest. 106, 245-252.
27. Lacroix-Desmazes, S., Misra, N., Bayry, J., Artaud, C, Drayton, B., Kaveri, S. V., Kazatchkine, M. D. (2002) Pathophysiology of inhibitors to factor VIII in patients with haemophilia A. Haemophilia 8, 273-279.
28. Getts, D. R, Shankar, S., Chastain, E. M., Martin, A, Getts, M. T., Wood, K, Miller, S. D. (2011) Current landscape for T-cell targeting in autoimmunity and transplantation. Immunotherapy 3, 853-870.
29. Elyaman, W., Khoury, S. J., Scott, D. W., De Groot, A. S. (2011) Potential application of Tregitopes as immunomodulating agents in multiple sclerosis. Neurol. Res. Int. 2011, 256460.
30. Van der Marel, S., Majowicz, A, Kwikkers, K, van Logtenstein, R, te Velde, A. A, De Groot, A. S., Meijer, S. L., van Deventer, S. J., Petry, H., Hommes, D. W., Ferreira, V. (2012) Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis. World J. Gastroenterol. 18, 4288-4299.
31. Scott, D. W., De Groot, A. S. (2010) Can we prevent immunogenicity of human protein drugs? Ann. Rheum. Dis. 69 (Suppl. 1), i72-i76.
32. Su, Y, Zhang, A. H., Noben-Trauth, N., Scott, D. W. (2011) B-cell gene therapy for tolerance induction: host but not donor B-cell derived IL-10 is necessary for tolerance. Front. Microbiol. 2, 154.
33. Su, Y, Zhang, A. H., Li, X., Owusu-Boaitey, N., Skupsky, J., Scott, D. W. (2011) B cells "transduced" with TAT-fusion proteins can induce tolerance and protect mice from diabetes and EAE. Clin. Immunol. 140, 260-267.
34. Su, Y, Carey, G., Maric, M., Scott, D. W. (2008) B cells induce tolerance by presenting endogenous peptide-IgG on MHC class II molecules via an IFN-7-inducible lysosomal thiol reductase-dependent pathway. J. Immunol. 181, 1153-1160.
35. Litzinger, M. T., Su, Y, Lei, T. C, Soukhareva, N., Scott, D. W. (2005) Mechanisms of gene therapy for tolerance: B7 signaling is required for peptide-IgG gene-transferred tolerance induction. J. Immunol. 175, 780-787.
36. Lei, T. C, Su, Y, Scott, D. W. (2005) Tolerance induction via a B-cell delivered gene therapy-based protocol: optimization and role of the Ig scaffold. Cell. Immunol. 235, 12-20.
37. Kang, Y, Melo, M., Deng, E., Tisch, R, El-Amine, M., Scott, D. W. (1999) Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsiveness. Proc. Natl. Acad. Sci. USA 96, 8609-8614.